The role of peroxisome proliferator-activated receptors in colorectal cancer

PPAR Research

Volumn , Issue , 2012, Pages

  Park, Joo In ^a   Kwak, Jong Young ^a  

^a Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BETA CATENIN; CHENODEOXYCHOLIC ACID; CIGLITAZONE; CYCLIN DEPENDENT KINASE; CYCLOOXYGENASE 2; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 8; LITHOCHOLIC ACID; MATRIX METALLOPROTEINASE; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PREGNANE X RECEPTOR; ROSIGLITAZONE; SURVIVIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VITAMIN D RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; DOWN REGULATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FATTY ACID OXIDATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; UBIQUITINATION; UPREGULATION;

EID: 84867379854     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/876418     Document Type: Review

References (138)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010. CA Cancer Journal for Clinicians 2010 60 5 277 300 2-s2.0-77955635233 10.3322/caac.20073
3. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002. CA Cancer Journal for Clinicians 2005 55 2 74 108 2-s2.0-14944385553 (Pubitemid 40372904)
4. Waters J., Cunningham D., The changing face of chemotherapy in colorectal cancer. British Journal of Cancer 2001 84 1 1 7 2-s2.0-0035136962 10.1054/bjoc.2000.1552 (Pubitemid 32102495)
5. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R. M., The nuclear receptor super-family: the second decade. Cell 1995 83 6 835 839 2-s2.0-0012473279
6. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0 (Pubitemid 20356241)
7. Schoonjans K., Staels B., Auwerx J., The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochimica et Biophysica Acta 1996 1302 2 93 109 2-s2.0-0030602866 10.1016/0005-2760(96)00066-5 (Pubitemid 26247079)
8. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 2000 43 4 527 550 2-s2.0-0033998334 10.1021/jm990554g (Pubitemid 30127149)
9. 2 a natural ligand for peroxisome proliferator-activated receptor γ (PPAR γ), in cancer. Cellular and Genetic Practices for Translational Medicine 2011 Research Signpost 169 195
10. Grau R., Punzón C., Fresno M., Iiguez M. A., Peroxisome- proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochemical Journal 2006 395 1 81 88 2-s2.0-33645562489 10.1042/BJ20050964
11. Rosenberg L., Palmer J. R., Zauber A. G., Warshauer M. E., Stolley P. D., Shapiro S., A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. Journal of the National Cancer Institute 1991 83 5 355 358 2-s2.0-0026417761
12. Reddy B. S., Rao C. V., Seibert K., Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Research 1996 56 20 4566 4569 2-s2.0-0029794742 (Pubitemid 26338047)
13. Thun M. J., Namboodiri M. M., Heath C. W. Jr., Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine 1991 325 23 1593 1596 2-s2.0-0025998557
14. Logan R. F. A., Little J., Hawtin P. G., Hardcastle J. D., Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. British Medical Journal 1993 307 6899 285 289 2-s2.0-0027237664 (Pubitemid 23220843)
15. Schreinemachers D. M., Everson R. B., Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994 5 2 138 146 2-s2.0-0028325496 (Pubitemid 24073387)
16. Kujubu D. A., Fletcher B. S., Varnum B. C., Lim R. W., Herschman H. R., TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. The Journal of Biological Chemistry 1991 266 20 12866 12872 2-s2.0-0025871150
17. Jones D. A., Carlton D. P., McIntyre T. M., Zimmerman G. A., Prescott S. M., Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. The Journal of Biological Chemistry 1993 268 12 9049 9054 2-s2.0-0027468941 (Pubitemid 23118701)
18. DuBois R. N., Awad J., Morrow J., Roberts L. J. II, Bishop P. R., Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor- α and phorbol ester. Journal of Clinical Investigation 1994 93 2 493 498 2-s2.0-0028344102 (Pubitemid 24072787)
19. Inoue H., Yokoyama C., Hara S., Tone Y., Tanabe T., Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. The Journal of Biological Chemistry 1995 270 42 24965 24971 2-s2.0-0028824312 10.1074/jbc.270.42.24965
20. Subbaramaiah K., Telang N., Ramonetti J. T., Araki R., DeVito B., Weksler B. B., Dannenberg A. J., Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Research 1996 56 19 4424 4429 2-s2.0-0029783253 (Pubitemid 26330450)
21. Mestre J. R., Subbaramaiah K., Sacks P. G., Schantz S. P., Tanabe T., Inoue H., Dannenberg A. J., Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Research 1997 57 14 2890 2895 2-s2.0-0030747815 (Pubitemid 27315035)
22. Tsujii M., Kawano S., Dubois R. N., Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America 1997 94 7 3336 3340 2-s2.0-0030952695 10.1073/pnas.94.7.3336 (Pubitemid 27157312)
23. Tsujii M., Dubois R. N., Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83 3 493 501 2-s2.0-0028803728
24. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., Dubois R. N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998 93 5 705 716 2-s2.0-0003504049 10.1016/S0092-8674(00)81433-6 (Pubitemid 28257578)
25. Masunaga R., Kohno H., Dhar D. K., Ohno S., Shibakita M., Kinugasa S., Yoshimura H., Tachibana M., Kubota H., Nagasue N., Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clinical Cancer Research 2000 6 10 4064 4068 2-s2.0-0033761153
26. Craven P. A., Pfanstiel J., DeRubertis F. R., Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation and reactive oxygen formation by bile acids. Journal of Clinical Investigation 1987 79 2 532 541 2-s2.0-0023150913 (Pubitemid 17009690)
27. Narisawa T., Magadia N. E., Weisburger J. H., Wynder E. L., Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. Journal of the National Cancer Institute 1974 53 4 1093 1097 2-s2.0-0016209908
28. Allinger U. G., Johansson G. K., Gustafsson J. A., Rafter J. J., Shift from a mixed to a lactovegetarian diet: influence on acidic lipids in fecal watera potential risk factor for colon cancer. American Journal of Clinical Nutrition 1989 50 5 992 996 2-s2.0-0024419597 (Pubitemid 19280024)
29. Makishima M., Okamoto A. Y., Repa J. J., Tu H., Learned R. M., Luk A., Hull M. V., Lustig K. D., Mangelsdorf D. J., Shan B., Identification of a nuclear receptor for bite acids. Science 1999 284 5418 1362 1365 2-s2.0-0033591297 10.1126/science.284.5418.1362 (Pubitemid 29289663)
30. Parks D. J., Blanchard S. G., Bledsoe R. K., Chandra G., Consler T. G., Kliewer S. A., Stimmel J. B., Willson T. M., Zavacki A. M., Moore D. D., Lehmann J. M., Bile acids: natural ligands for an orphan nuclear receptor. Science 1999 284 5418 1365 1368 2-s2.0-0033591387 10.1126/science.284.5418.1365 (Pubitemid 29289664)
31. Staudinger J. L., Goodwin B., Jones S. A., Hawkins-Brown D., MacKenzie K. I., LaTour A., Liu Y., Klaassen C. D., Brown K. K., Reinhard J., Willson T. M., Koller B. H., Kliewer S. A., The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proceedings of the National Academy of Sciences of the United States of America 2001 98 6 3369 3374 2-s2.0-0035853165 10.1073/pnas.051551698 (Pubitemid 32220852)
32. Makishima M., Lu T. T., Xie W., Whitfield G. K., Domoto H., Evans R. M., Haussler M. R., Mangelsdorf D. J., Vitamin D receptor as an intestinal bile acid sensor. Science 2002 296 5571 1313 1316 2-s2.0-0037123667 10.1126/science. 1070477 (Pubitemid 34522785)
33. Oshio H., Abe T., Onogawa T., Ohtsuka H., Sato T., Ii T., Fukase K., Muto M., Katayose Y., Oikawa M., Rikiyama T., Egawa S., Unno M., Peroxisome proliferator-activated receptor α activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. Journal of Gastroenterology 2008 43 7 538 549 2-s2.0-48449095008 10.1007/s00535-008-2188-3
34. Tong J. L., Zhang C. P., Nie F., Xu X. T., Zhu M. M., Xiao S. D., Ran Z. H., MicroRNA 506 regulates expression of PPAR α in hydroxycamptothecin- resistant human colon cancer cells. FEBS Letters 2011 585 22 3560 3568 10.1016/j.febslet.2011.10.021
35. Evans R. M., The steroid and thyroid hormone receptor superfamily. Science 1988 240 4854 889 895 2-s2.0-0023913120
36. Schoonjans K., Martin G., Staels B., Auwerx J., Peroxisome proliferator-activated receptors, orphans with ligands and functions. Current Opinion in Lipidology 1997 8 3 159 166 2-s2.0-0030794057 10.1097/00041433- 199706000-00006 (Pubitemid 27290462)
37. Mansure J. J., Nassim R., Kassouf W., Peroxisome proliferator-activated receptor γ in bladder cancer: a promising therapeutic target. Cancer Biology and Therapy 2009 8 7 1 9 2-s2.0-66149157824
38. Dubois R. N., Gupta R., Brockman J., Reddy B. S., Krakow S. L., Lazar M. A., The nuclear eicosanoid receptor, PPAR γ is aberrantly expressed in colonic cancers. Carcinogenesis 1998 19 1 49 53 2-s2.0-0031844535 10.1093/carcin/19.1.49 (Pubitemid 28376825)
39. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052 2-s2.0-0031671246 10.1038/2030 (Pubitemid 28417337)
40. Mueller E., Sarraf P., Tontonoz P., Evans R. M., Martin K. J., Zhang M., Fletcher C., Singer S., Spiegelman B. M., Terminal differentiation of human breast cancer through PPAR γ Molecular Cell 1998 1 3 465 470 2-s2.0-0031993322 (Pubitemid 128378895)
41. Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P., Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Research 1998 58 15 3344 3352 2-s2.0-0032145363 (Pubitemid 28371075)
42. Krishnan A., Nair S. A., Pillai M. R., Biology of PPAR γ in cancer: a critical review on existing lacunae. Current Molecular Medicine 2007 7 6 532 540 2-s2.0-35448982383 10.2174/156652407781695765 (Pubitemid 47618050)
43. de la Lastra C. A., Sánchez-Fidalgo S., Villegas I., Motilva V., New pharmacological perspectives and therapeutic potential of PPAR- γ agonists. Current Pharmaceutical Design 2004 10 28 3505 3524 2-s2.0-5744232398 10.2174/1381612043382909 (Pubitemid 39378330)
44. Wang T., Xu J., Yu X., Yang R., Han Z. C., Peroxisome proliferator-activated receptor γ in malignant diseases. Critical Reviews in Oncology/Hematology 2006 58 1 1 14 10.1016/j.critrevonc.2005.08.011
45. Sarraf P., Mueller E., Smith W. M., Wright H. M., Kum J. B., Aaltonen L. A., de la Chapelle A., Spiegelman B. M., Eng C., Loss-of-function mutations in PPAR γ associated with human colon cancer. Molecular Cell 1999 3 6 799 804 2-s2.0-0033152206 10.1016/S1097-2765(01)80012-5 (Pubitemid 29323058)
46. Ikezoe T., Miller C. W., Kawano S., Heaney A., Williamson E. A., Hisatake J., Green E., Hofmann W., Taguchi H., Koeffler H. P., Mutational analysis of the peroxisome proliferator-activated receptor γ in human malignancies. Cancer Research 2001 61 13 5307 5310 2-s2.0-0035394518 (Pubitemid 32681569)
47. Patel L., Pass I., Coxon P., Downes C. P., Smith S. A., Macphee C. H., Tumor suppressor and anti-inflammatory actions of PPAR γ agonists are mediated via upregulation of PTEN. Current Biology 2001 11 10 764 768 2-s2.0-0035873953 10.1016/S0960-9822(01)00225-1 (Pubitemid 32442793)
48. Dai Y., Qiao L., Chan K. W., Zou B., Ma J., Lan H. Y., Gu Q., Li Z., Wang Y., Wong B. L. W., Wong B. C. Y., Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. International Journal of Cancer 2008 122 12 2858 2863 2-s2.0-43049093730 10.1002/ijc.23443 (Pubitemid 351631390)
49. Wang D., Ning W., Xie D., Guo L., Dubois R. N., Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ -induced apoptosis in colorectal cancer cells. Oncogene 2012 31 8 1013 1023 2-s2.0-79960298051 10.1038/onc.2011.299
50. Qiao L., Dai Y., Gu Q., Chan K. W., Zou B., Ma J., Wang J., Lan H. Y., Wong B. C. Y., Downregulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer. Molecular Cancer Therapeutics 2008 7 7 2203 2211 2-s2.0-51049118824 10.1158/1535-7163.MCT-08-0326
51. Lee C. J., Han J. S., Seo C. Y., Park T. H., Kwon H. C., Jeong J. S., Kim I. H., Yun J., Bae Y. S., Kwak J. Y., Park J. I., Pioglitazone, a synthetic ligand for PPAR γ induces apoptosis in RB-deficient human colorectal cancer cells. Apoptosis 2006 11 3 401 411 2-s2.0-33646387693 10.1007/s10495-006-4003-z
52. Ban J. O., Kwak D. H., Oh J. H., Park E. J., Cho M. C., Song H. S., Song M. J., Han S. B., Moon D. C., Kang K. W., Hong J. T., Suppression of NF- κ B and GSK-3 β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chemico-Biological Interactions 2010 188 1 75 85 2-s2.0-77956172120 10.1016/j.cbi.2010.06.001
53. Kim E., Chen F., Wang C. C., Harrison L. E., CDK5 is a novel regulatory protein in PPAR γ ligand-induced antiproliferation. International Journal of Oncology 2006 28 1 191 194 2-s2.0-33644809309
54. Kitamura S., Miyazaki Y., Hiraoka S., Nagasawa Y., Toyota M., Takakura R., Kiyohara T., Shinomura Y., Matsuzawa Y., PPAR γ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. International Journal of Cancer 2001 94 3 335 342 2-s2.0-0035497756 10.1002/ijc.1470 (Pubitemid 32906062)
55. Chen A., Xu J., Activation of PPAR γ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. American Journal of PhysiologyGastrointestinal and Liver Physiology 2005 288 3 G447 G456 2-s2.0-13844306722 10.1152/ajpgi.00209.2004 (Pubitemid 40261742)
56. Chen F., Harrison L. E., Ciglitazone-induced cellular anti-proliferation increases p27 kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cellular Signalling 2005 17 7 809 816 2-s2.0-14844354335 10.1016/j.cellsig.2004.11.002 (Pubitemid 40353651)
57. Chen F., Kim E., Wang C. C., Harrison L. E., Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cellular Signalling 2005 17 12 1572 1577 2-s2.0-24344441541 10.1016/j.cellsig.2005.03.012 (Pubitemid 41253996)
58. 2 upregulates krüppel-like factor 4 expression independently of peroxisome proliferator-activated receptor γ by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Molecular Pharmacology 2005 68 5 1203 1213 2-s2.0-27544446292 10.1124/mol.105.014944 (Pubitemid 41539978)
59. Rageul J., Mottier S., Jarry A., Shah Y., Théoleyre S., Masson D., Gonzalez F. J., Laboisse C. L., Denis M. G., KLF4-dependent, PPAR γ -induced expression of GPA33 in colon cancer cell lines. International Journal of Cancer 2009 125 12 2802 2809 2-s2.0-72449151427 10.1002/ijc.24683
60. Chen G. G., Xu H., Lee J. F. Y., Subramaniam M., Leung K. L., Wang S. H., Chan U. P. F., Spelsberg T. C., 15-Hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. International Journal of Cancer 2003 107 5 837 843 2-s2.0-0242363581 10.1002/ijc.11447 (Pubitemid 37339740)
61. Chen G. G., Lee J. F. Y., Wang S. H., Chan U. P. F., Ip P. C., Lau W. Y., Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF- κ B in human colon cancer. Life Sciences 2002 70 22 2631 2646 2-s2.0-0037134255 10.1016/S0024-3205(02) 01510-2 (Pubitemid 34310556)
62. Toaldo C., Pizzimenti S., Cerbone A., Pettazzoni P., Menegatti E., Daniela B., Minelli R., Giglioni B., Dianzani M. U., Ferretti C., Barrera G., PPAR γ ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. Journal of Cellular and Molecular Medicine 2010 14 6 1347 1357 2-s2.0-77955132089 10.1111/j.1582-4934.2009.00966.x
63. Yoshizumi T., Ohta T., Ninomiya I., Terada I., Fushida S., Fujimura T., Nishimura G. I., Shimizu K., Yi S., Miwa K., Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. International Journal of Oncology 2004 25 3 631 639 2-s2.0-16644393169
64. Dong Y. D., Wang X. P., Wu K., Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor γ involves angiogenesis inhibition. World Journal of Gastroenterology 2009 15 4 441 448 2-s2.0-59249086761 10.3748/wjg.15.441
65. Shen D., Deng C., Zhang M., Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells. Postgraduate Medical Journal 2007 83 980 414 419 2-s2.0-34250773317 10.1136/pmj.2006.052761 (Pubitemid 46960828)
66. 2 inhibits the inflammatory response in primary rat astrocytes via downregulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF- κ B-p300 pathway independent of peroxisome proliferator-activated receptor γ Journal of Immunology 2004 173 8 5196 5208 2-s2.0-6344278016 (Pubitemid 39387803)
67. 2 Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4668 4673 2-s2.0-0033551134 (Pubitemid 29190394)
68. 2 ameliorates ischemic acute renal failure. Cardiovascular Research 2004 61 3 630 643 2-s2.0-10744231560 10.1016/j.cardiores.2003.10.024 (Pubitemid 38210168)
69. Inoue H., Tanabe T., Umesono K., Feedback control of cyclooxygenase-2 expression through PPAR γ The Journal of Biological Chemistry 2000 275 36 28028 28032 2-s2.0-0034623232 10.1074/jbc.M001387200
70. 2 is acting as a dual agent on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage 2002 10 11 845 848 2-s2.0-0036854541 10.1053/joca.2002.0835 (Pubitemid 35378769)
71. Subbaramaiah K., Lin D. T., Hart J. C., Dannenberg A. J., Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. The Journal of Biological Chemistry 2001 276 15 12440 12448 2-s2.0-0035853840 10.1074/jbc.M007237200
72. 2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochemical Pharmacology 2006 72 11 1516 1528 2-s2.0-33750530167 10.1016/j.bcp.2006.07.030 (Pubitemid 44666747)
73. 2 inhibits IL-10 and IL-12 production by macrophages. Biochemical and Biophysical Research Communications 2001 283 2 344 346 2-s2.0-0034809335 10.1006/bbrc.2001.4783 (Pubitemid 32924695)
74. Yamada K. M., Araki M., Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. Journal of Cell Science 2001 114 13 2375 2382 2-s2.0-0034921007 (Pubitemid 32684793)
75. Altieri D. C., Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 2003 3 1 46 54 2-s2.0-0037267333 10.1038/nrc968 (Pubitemid 37328886)
76. Kawasaki H., Altieri D. C., Lu C. D., Toyoda M., Tenjo T., Tanigawa N., Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Research 1998 58 22 5071 5074 2-s2.0-0032533494 (Pubitemid 28521163)
77. Sarela A. I., Scott N., Ramsdale J., Markham A. F., Guillou P. J., Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Annals of Surgical Oncology 2001 8 4 305 310 2-s2.0-0035011885 10.1245/aso.2001.8.4.305 (Pubitemid 32422855)
78. Kaufmann T., Strasser A., Jost P. J., Fas death receptor signalling: roles of Bid and XIAP. Cell Death and Differentiation 2012 19 1 42 50 10.1038/cdd.2011.121
79. Ghosh S., May M. J., Kopp E. B., NF- κ B and rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998 16 225 260 2-s2.0-0031897632 10.1146/annurev.immunol.16.1.225 (Pubitemid 28183365)
80. Greten F. R., Eckmann L., Greten T. F., Park J. M., Li Z. W., Egan L. J., Kagnoff M. F., Karin M., IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004 118 3 285 296 2-s2.0-4043088499 10.1016/j.cell.2004.07.013 (Pubitemid 39061110)
81. Pikarsky E., Porat R. M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Uriell-Shoval S., Galun E., Ben-Neriah Y., NF- κ B functions as a tumour promoter in inflammation-associated cancer. Nature 2004 431 7007 461 466 2-s2.0-4644324186 10.1038/nature02924 (Pubitemid 39329586)
82. Garg A., Aggarwal B. B., Nuclear transcription factor- κ B as a target for cancer drug development. Leukemia 2002 16 6 1053 1068 2-s2.0-0036275467 10.1038/sj/leu/2402482 (Pubitemid 34618844)
83. Fajas L., Egler V., Reiter R., Miard S., Lefebvre A. M., Auwerx J., PPAR γ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 2003 22 27 4186 4193 2-s2.0-0037699445 10.1038/sj.onc.1206530 (Pubitemid 36876239)
84. Lu S., Yu G., Zhu Y., Archer M. C., Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. International Journal of Cancer 2005 116 6 847 852 2-s2.0-23944522756 10.1002/ijc.21142 (Pubitemid 41209189)
85. Gately S., Li W. W., Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology 2004 31 7 2 11 2-s2.0-3042748129 10.1016/j.seminoncol.2004.03.040 (Pubitemid 38879409)
86. Dang D. T., Pevsner J., Yang V. W., The biology of the mammalian Krüppel-like family of transcription factors. International Journal of Biochemistry and Cell Biology 2000 32 11-12 1103 1121 2-s2.0-0034532675 10.1016/S1357-2725(00)00059-5 (Pubitemid 32008299)
87. Shie J. L., Chen Z. Y., O'Brien M. J., Pestell R. G., Lee M. E., Tseng C. C., Role of gut-enriched Krüppel-like factor in colonic cell growth and differentiation. American Journal of PhysiologyGastrointestinal and Liver Physiology 2000 279 4 G806 G814 2-s2.0-0033680714
88. Bieker J. J., Krüppel-like factors: three fingers in many pies. The Journal of Biological Chemistry 2001 276 37 34355 34358 2-s2.0-0035860820 10.1074/jbc.R100043200
89. Chen Z. Y., Shie J. L., Tseng C. C., Upregulation of gut-enriched krüppel-like factor by interferon- γ in human colon carcinoma cells. FEBS Letters 2000 477 1-2 67 72 2-s2.0-0034647881 10.1016/S0014-5793(00)01764-6 (Pubitemid 30438859)
90. Dang D. T., Chen X., Feng J., Torbenson M., Dang L. H., Yang V. W., Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003 22 22 3424 3430 2-s2.0-0037780740 10.1038/sj.onc.1206413 (Pubitemid 36713740)
91. Dhaene K., van Marck E., Parwaresch R., Telomeres, telomerase and cancer: an up-date. Virchows Archiv 2000 437 1 1 16 2-s2.0-0033945105 10.1007/s004280000189 (Pubitemid 30446910)
92. Shay J. W., Wright W. E., Telomerase therapeutics for cancer: challenges and new directions. Nature Reviews Drug Discovery 2006 5 7 577 584 2-s2.0-33745679352 10.1038/nrd2081 (Pubitemid 43971192)
93. Hiyama E., Yokoyama T., Tatsumoto N., Hiyama K., Imamura Y., Murakami Y., Kodama T., Piatyszek M. A., Shay J. W., Matsuura Y., Telomerase activity in gastric cancer. Cancer Research 1995 55 15 3258 3262 2-s2.0-0029131243
94. Chadeneau C., Hay K., Hirte H. W., Gallinger S., Bacchetti S., Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Research 1995 55 12 2533 2536 2-s2.0-0029013631
95. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E., Extension of life-span by introduction of telomerase into normal human cells. Science 1998 279 5349 349 352 2-s2.0-0010045614 10.1126/science.279.5349.349 (Pubitemid 28063364)
96. Vaziri H., Benchimol S., Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Current Biology 1998 8 5 279 282 2-s2.0-0032567967 (Pubitemid 28111458)
97. Meeker A. K., de Marzo A. M., Recent advances in telomere biology: implications for human cancer. Current Opinion in Oncology 2004 16 1 32 38 2-s2.0-2442542568 10.1097/00001622-200401000-00007 (Pubitemid 38703469)
98. Morales C. P., Holt S. E., Ouellette M., Kaur K. J., Yan Y., Wilson K. S., White M. A., Wright W. E., Shay J. W., Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genetics 1999 21 1 115 118 2-s2.0-0032924343 10.1038/5063 (Pubitemid 29036296)
99. Hahn W. C., Stewart S. A., Brooks M. W., York S. G., Eaton E., Kurachi A., Beijersbergen R. L., Knoll J. H. M., Meyerson M., Weinberg R. A., Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine 1999 5 10 1164 1170 2-s2.0-0032828652 10.1038/13495 (Pubitemid 29474421)
100. Delhommeau F., Thierry A., Feneux D., Lauret E., Leclercq E., Courtier M. H., Sainteny F., Vainchenker W., Bennaceur-Griscelli A., Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 2002 21 54 8262 8271 2-s2.0-0037191931 10.1038/sj.onc.1206054 (Pubitemid 35477866)
101. Kawamata H., Tachibana M., Fujimori T., Imai Y., Differentiation-inducing therapy for solid tumors. Current Pharmaceutical Design 2006 12 3 379 385 2-s2.0-33644862596 10.2174/138161206775201947
102. Risau W., Mechanisms of angiogenesis. Nature 1997 386 6626 671 674 2-s2.0-0030952289 (Pubitemid 27193480)
103. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
104. Carmeliet P., VEGF as a key mediator of angiogenesis in cancer. Oncology 2005 69 3 4 10 2-s2.0-27944473690 10.1159/000088478 (Pubitemid 41680947)
105. Lee J. C., Chow N. H., Wang S. T., Huang S. M., Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. European Journal of Cancer 2000 36 6 748 753 2-s2.0-0034075041 10.1016/S0959-8049(00)00003-4 (Pubitemid 30179746)
106. Poon R. T. P., Fan S. T., Wong J., Clinical implications of circulating angiogenic factors in cancer patients. Journal of Clinical Oncology 2001 19 4 1207 1225 2-s2.0-0035865450 (Pubitemid 32176299)
107. Sternlicht M. D., Werb Z., How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 2001 17 463 516 2-s2.0-0035188727 10.1146/annurev.cellbio.17.1.463 (Pubitemid 33096184)
108. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621 2-s2.0-33750497844 10.1016/j.bcp.2006.06.029 (Pubitemid 44666739)
109. Minuzzo S., Moserle L., Indraccolo S., Amadori A., Angiogenesis meets immunology: cytokine gene therapy of cancer. Molecular Aspects of Medicine 2007 28 1 59 86 2-s2.0-33847314184 10.1016/j.mam.2006.12.008
110. Choi I. K., Kim Y. H., Kim J. S., Seo J. H., PPAR- γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Investigational New Drugs 2008 26 3 283 288 2-s2.0-42549146102 10.1007/s10637-007-9108-x
111. 2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 2008 29 4 688 695 2-s2.0-41849150053 10.1093/carcin/bgm299 (Pubitemid 351494155)
112. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., Nishizawa Y., Peroxisome proliferator-activated receptor- γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochemical and Biophysical Research Communications 2000 271 3 571 574 2-s2.0-0034685660 10.1006/bbrc.2000.2665 (Pubitemid 30444669)
113. Inoue M., Itoh H., Tanaka T., Chun T. H., Doi K., Fukunaga Y., Sawada N., Yamshita J., Masatsugu K., Saito T., Sakaguchi S., Sone M., Yamahara K. I., Yurugi T., Nakao K., Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor- γ Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 4 560 566 2-s2.0-0035049227 (Pubitemid 32323389)
114. Chintalgattu V., Harris G. S., Akula S. M., Katwa L. C., PPAR- γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovascular Research 2007 74 1 140 150 2-s2.0-33847674375 10.1016/j.cardiores.2007.01.010 (Pubitemid 46366953)
115. 2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis 2009 30 4 645 654 2-s2.0-64349099334 10.1093/carcin/bgp012
116. Lefebvre A. M., Chen I., Desreumaux P., Najib J., Fruchart J. C., Geboes K., Briggs M., Heyman R., Auwerx J., Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-AP C Min / + mice. Nature Medicine 1998 4 9 1053 1057 2-s2.0-0031694577 10.1038/2036 (Pubitemid 28417338)
117. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U. T., Baird S. M., Thomazy V. A., Evans R. M., Activators of the nuclear receptor PPAR γ enhance colon polyp formation. Nature Medicine 1998 4 9 1058 1061 2-s2.0-0031667938 10.1038/2042 (Pubitemid 28417339)
118. Karim R. Z., Tse G. M. K., Putti T. C., Scolyer R. A., Lee C. S., The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004 36 2 120 128 2-s2.0-1942537708 10.1080/00313020410001671957 (Pubitemid 38507872)
119. Wang D., Dubois R. N., Prostaglandins and cancer. Gut 2006 55 1 115 122 2-s2.0-29244449354 10.1136/gut.2004.047100 (Pubitemid 41820645)
120. 2 upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor- γ Acta Biochimica Polonica 2003 50 3 677 689 2-s2.0-17144444084 (Pubitemid 38623801)
121. Varnat F., Heggeler B. B., Grisel P., Boucard N., Corthésy-Theulaz I., Wahli W., Desvergne B., PPAR β / δ regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 2006 131 2 538 553 2-s2.0-33746682493 10.1053/j.gastro.2006.05.004 (Pubitemid 44160696)
122. He T. C., Chan T. A., Vogelstein B., Kinzler K. W., PPAR δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999 99 3 335 345 2-s2.0-0033615352 10.1016/S0092-8674(00)81664-5 (Pubitemid 29519912)
123. Gupta R. A., Tan J., Krause W. F., Geraci M. W., Willson T. M., Dey S. K., Dubois R. N., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2000 97 24 13275 13280 2-s2.0-0034700110 10.1073/pnas.97.24.13275
124. Park B. H., Vogelstein B., Kinzler K. W., Genetic disruption of PPAR
125. Shao J., Sheng H., Dubois R. N., Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Research 2002 62 11 3282 3288 2-s2.0-0036606010 (Pubitemid 34602426)
126. Di-Poï N., Tan N. S., Michalik L., Wahli W., Desvergne B., Antiapoptotic role of PPAR β in keratinocytes via transcriptional control of the Akt1 signaling pathway. Molecular Cell 2002 10 4 721 733 2-s2.0-0036771764 10.1016/S1097-2765(02)00646-9 (Pubitemid 35335629)
127. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S. K., Dubois R. N., Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2006 103 50 19069 19074 2-s2.0-34047243022 10.1073/pnas.0607948103 (Pubitemid 350002829)
128. Kwak H., Hwang I., Kim J. H., Mee Y. K., Yang J. S., Jeong S., Modulation of transcription by the peroxisome proliferator-activated receptor δ -binding RNA aptamer in colon cancer cells. Molecular Cancer Therapeutics 2009 8 9 2664 2673 2-s2.0-70349499011 10.1158/1535-7163.MCT-09-0214
129. Reed K. R., Sansom O. J., Hayes A. J., Gescher A. J., Winton D. J., Peters J. M., Clarke A. R., PPAR δ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 2004 23 55 8992 8996 2-s2.0-10644231009 10.1038/sj.onc.1208143 (Pubitemid 39657790)
130. Peters J. M., Gonzalez F. J., Sorting out the functional role(s) of peroxisome proliferator-activated receptor- β / δ (PPAR β / δ) in cell proliferation and cancer. Biochimica et Biophysica Acta 2009 1796 2 230 241 2-s2.0-70349177505 10.1016/j.bbcan.2009.06.002
131. Peters J. M., Hollingshead H. E., Gonzalez F. J., Role of peroxisome-proliferator-activated receptor β / δ (PPAR β / δ) in gastrointestinal tract function and disease. Clinical Science 2008 115 3-4 107 127 2-s2.0-48949102050 10.1042/CS20080022
132. Nadra K., Anghel S. I., Joye E., Tan N. S., Basu-Modak S., Trono D., Wahli W., Desvergne B., Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β / δ Molecular and Cellular Biology 2006 26 8 3266 3281 2-s2.0-33645802802 10.1128/MCB.26.8.3266-3281.2006
133. Zuo X., Peng Z., Moussalli M. J., Morris J. S., Broaddus R. R., Fischer S. M., Shureiqi I., Targeted genetic disruption of peroxisome proliferator-activated receptor- δ and colonic tumorigenesis. Journal of the National Cancer Institute 2009 101 10 762 767 2-s2.0-66849099322 10.1093/jnci/djp078
134. Harman F. S., Nicol C. J., Marin H. E., Ward J. M., Gonzalez F. J., Peters J. M., Peroxisome proliferator-activated receptor- δ attenuates colon carcinogenesis. Nature Medicine 2004 10 5 481 483 2-s2.0-2442708845 10.1038/nm1026 (Pubitemid 38667905)
135. Peters J. M., Lee S. S. T., Li W., Ward J. M., Gavrilova O., Everett C., Reitman M. L., Hudson L. D., Gonzalez F. J., Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ). Molecular and Cellular Biology 2000 20 14 5119 5128 2-s2.0-0033625677 10.1128/MCB.20.14.5119-5128.2000 (Pubitemid 30431565)
136. Kopelovich L., Yin Y., Russell R. G., Dettin L. E., Bai R., Wei Z. L., Kozikowski A. P., Kopelovich L., Glazer R. I., Peroxisome proliferator-activator receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Research 2005 65 9 3950 3957 (Pubitemid 40616378)
137. Yang L., Olsson B., Pfeifer D., Jönsson J. I., Zhou Z. G., Jiang X., Fredriksson B. A., Zhang H., Sun X. F., Knockdown of peroxisome proliferator-activated receptor- β induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene 2010 29 4 516 526 2-s2.0-75749150060 10.1038/onc.2009.370
138. Wu K. K., Liou J. Y., Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPAR δ →14-3-3 ε pathway. Methods in Molecular Biology 2009 512 295 307 2-s2.0-67650354231 10.1007/978-1-60327-530-916